ArticleAdvances in therapy2025
Retrospective Analysis of Racial Differences in Treatment Patterns and Prostate-Specific Antigen Responses Among Patients with Prostate Cancer Treated with Relugolix in the Veterans Health Administration.
Article in Advances in therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06462014 (Description of Relugolix Use in Patients With Prostate Cancer), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Description of Relugolix Use in Patients With Prostate Cancer: An Analysis of National Veterans Affairs Health Care Network Data
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionRelugolix is the only oral androgen deprivation therapy (ADT) approved for advanced prostate cancer (PC). Real-world evidence on treatment patterns and prostate-specific antigen (PSA) responses of relugolix, especially as a function of race, remain limited. This study assessed these outcomes and compared differences between Black and White patients.
methodsVeterans Health Administration data were analyzed to identify male adults with PC who initiated relugolix between December 2020 and December 2023. Adherence to relugolix was assessed for up to 1 year after treatment initiation and was compared between races using generalized linear models. Discontinuation of relugolix, switching to another ADT, and initiating an add-on PC treatment were assessed using Kaplan-Meier analyses and compared between races using Cox regressions. PSA responses during relugolix treatment, including ≥ 50% and ≥ 90% decline from baseline and achieving < 0.2 ng/mL, were assessed among ADT-naïve patients.
resultsA total of 507 patients were identified (141 Black and 313 White patients). During the first 12 months of treatment, both races had > 90% adherence to relugolix with no significant differences between them. During follow-up (median 10.7 and 12.6 months for Black and White patients, respectively), 27.0% Black and 21.1% White patients discontinued relugolix; 9.2% Black and 3.8% White patients switched to another ADT; and 11.3% Black and 10.5% White patients initiated an add-on PC treatment. Among ADT-naïve patients, 87.2% Black and 87.2% White patients achieved PSA decline ≥ 50% from baseline; 69.2% and 64.1% achieved ≥ 90% decline; 51.3% and 47.4% achieved PSA < 0.2 ng/mL.
conclusionAdherence to relugolix was very high during the first year of treatment. These data support that in the real world, patients can adhere to relugolix with PSA responses on par with clinical trials regardless of race. Black patients were more likely to discontinue or switch to another ADT than White patients, but the reasons for this require further study.
trial registrationClinicalTrials.gov identifier, NCT06462014.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.